# Pancreatic cancer awareness and treatment developments

> Developing situation record from CLSTR: https://clstr.news/situations/pancreatic-cancer-awareness-and-treatment-developments
> Updated: 2026-11-17T14:54:19.000Z. Sources: 36. Developments: 2.

Medical awareness efforts have focused on pancreatic cancer through initiatives such as the “All Together We Can” campaign by PanCAN. This campaign seeks to raise 250 million US dollars over five years to support research, patient advocacy, and clinical trial access. In conjunction with World Pancreatic Cancer Day, new medical advancements have been reported. The European Commission has authorized the sale of Rasonque (daraxonrasib), developed by Revolution Medicines, for treating adults with metastatic pancreatic adenocarcinoma who have previously undergone systemic therapy. This authorization follows an accelerated assessment by the European Medicines Agency. In the phase III RASolute 302 clinical study, patients treated with the once-daily oral tablet showed a median overall survival of 12.4 to 13.2 months, compared to 6.7 months for those receiving standard chemotherapy. The drug also reportedly doubled the median time without disease progression from 3.6 to 7.2 months. The drug works by blocking RAS proteins to inhibit tumor growth and is indicated regardless of the presence of a Ras mutation. While the authorization applies across the EU, EEA, Iceland, Norway, and Liechtenstein, individual member states must determine pricing and reimbursement. In Italy, the Italian Medicines Agency is conducting a rolling review to expedite access, while patient associations in Spain are calling for expedited national funding processes. Technological progress is expanding in the diagnostic and surgical fields. In Spain, the ENDOGROUP at Centro Médico Teknon utilizes laser confocal endomicroscopy (EUS-nCLE) to differentiate between benign and malignant pancreatic cysts with high precision. Additionally, the Hospital Universitario Germans Trias i Pujol in Spain is employing Fujifilm Healthcare’s SYNAPSE 3D technology to create personalized anatomical models, which aids surgeons in planning complex procedures by visualizing tumor-vascular relationships.

## Claims

- In a study of 500 patients, those receiving daraxonrasib had a median survival of 12.4 months. (reported by 8 sources)
- Daraxonrasib increases survival from 6.7 to 13 months in patients previously treated with chemotherapy. (reported by 7 sources)
- The drug is approved regardless of the presence of a Ras mutation in the tumor. (reported by 6 sources)
- The European Commission approved Rasonque (daraxonrasib) for treating adult patients with metastatic pancreatic adenocarcinoma. (reported by 15 sources)
- Rasonque is indicated for patients who have already received at least one systemic therapy. (reported by 15 sources)
- Rasonque is administered once daily as an oral tablet. (reported by 10 sources)
- The European Medicines Agency (EMA) recommended the approval in October. (reported by 9 sources)
- The authorization applies to EU member states, the EEA, Iceland, Norway, and Liechtenstein. (reported by 7 sources)
- Daraxonrasib combined with chemotherapy reduces tumors in metastatic pancreatic cancer patients. (reported by 7 sources)
- The European Commission authorized the drug on November 16. (reported by 7 sources)
- Italy is awaiting final approval from the Italian Medicines Agency (AIFA). (reported by 5 sources)
- The clinical study was a phase 1-2 trial conducted in Spain. (reported by 2 sources)

## Timeline

### 2026-11-17: European Commission authorizes daraxonrasib for metastatic pancreatic cancer

The European Commission has approved daraxonrasib (Rasonque) for metastatic pancreatic cancer, showing it can nearly double median survival rates compared to standard chemotherapy.

36 sources. https://clstr.news/cluster/pancreatic-cancer-initiatives-launched-in-southern-italy

### 2026-11-05: Medical awareness initiatives focus on pancreatic cancer and acute porphyria

PanCAN launches a major fundraising campaign for pancreatic cancer research while medical awareness grows regarding the diagnostic challenges of acute porphyria.

2 sources. https://clstr.news/cluster/medical-awareness-initiatives-focus-on-pancreatic-cancer-and-acute-porphyria

---
Cite as: Pancreatic cancer awareness and treatment developments. CLSTR, https://clstr.news/situations/pancreatic-cancer-awareness-and-treatment-developments
